A new drug for treating ischemic stroke, LT3001 (trade name Odatroltide), has shown promising results in recent phase 2 clinical trials. Tom Devlin, MD, PhD, a stroke neurologist and medical director of CommonSpirit – Memorial Hospital – Neuroscience Institute, led the international research team. The findings were presented at the International Stroke Conference in New Orleans on February 6, 2026.
LT3001 is designed to dissolve blood clots in the brain while also providing neuroprotection to prevent further injury. According to Dr. Devlin, “We are incredibly excited about the positive results of our studies with LT3001. For years, standard stroke treatments have been limited by a narrow treatment time window, meaning many patients simply couldn’t receive them. Our research shows that LT3001 could potentially significantly extend this window and help patients who currently have very few options.”
The clinical trials included patients from various countries and showed that LT3001 was safe and effective even when administered up to 24 hours after the onset of stroke symptoms. This extended treatment window could allow more patients worldwide to benefit from the drug.
Key outcomes from the studies indicated improved recovery for patients receiving LT3001 compared to those given a placebo. The medication did not lead to an increase in serious bleeding complications—a common concern with other stroke drugs—and offered benefits beyond traditional treatment timeframes.
Memorial Hospital played a significant role as it was the top center in the United States for patient enrollment in these trials. Dr. Devlin noted, “Our participation in studies like this means we’re directly contributing to scientific advancements that can change lives. The consistent positive results across different trials strengthen our belief that LT3001 could significantly improve recovery and quality of life for stroke survivors.”
Phase 3 trials are planned before LT3001 becomes widely available. Dr. Devlin added, “We are moving forward with starting the last stage of LT3001 testing (phase 3) very soon. Simultaneously, we are also studying LT3001 in the subset of stroke patients who need emergency brain surgery for stroke—a thrombectomy procedure—to improve the outcomes of these patients, too.”
Memorial Hospital serves as one of CommonSpirit’s flagship hospitals and operates as a certified Comprehensive Stroke Center offering full emergency neurology and neurosurgery services at a high level.
Chi Memorial Hospital Georgia is part of CommonSpirit Health system and includes three hospitals and numerous care sites throughout Southeast Tennessee and Northwest Georgia (official website). The hospital has received recognition for its commitment to quality and patient safety (official website). Janelle Reilly serves as president (official website), leading efforts aimed at enhancing lives through superior care (official website).
For more information on treatment options available at Memorial Hospital Neuroscience Institute, visit commonspirit.org/services-specialties/stroke-care.
